Approximately 1 in 4 patients with NSCLC present with resectable disease. Although surgery is potentially curative, 30%-50% of patients relapse. Studies have shown that neoadjuvant, adjuvant, and perioperative chemoimmunotherapy improve outcomes. The Checkmate 77T trial explored if perioperative platinum-based chemotherapy plus nivolumab, surgical resection, then adjuvant nivolumab further improved outcomes including EFS. 1 .
Keyphrases
- early stage
- locally advanced
- cardiac surgery
- small cell lung cancer
- patients undergoing
- rectal cancer
- end stage renal disease
- prognostic factors
- ejection fraction
- newly diagnosed
- chronic kidney disease
- minimally invasive
- advanced non small cell lung cancer
- clinical trial
- peritoneal dialysis
- squamous cell carcinoma
- type diabetes
- patient reported outcomes
- acute coronary syndrome
- atrial fibrillation
- percutaneous coronary intervention
- weight loss